Import from "@/components/mdx"

IGF-1 Lab Test: Drugs That Distort Your Results and What Your Levels Mean

What IGF-1 Actually Measures and Why You Should Care

IGF-1 is a protein made mostly in the liver in response to growth hormone (GH) pulses from the pituitary. Because GH itself spikes and crashes throughout the day, a single GH blood draw tells you almost nothing. IGF-1 has a much longer half-life, roughly 15 to 20 hours, which makes it the practical surrogate for integrated GH secretion over the previous 24 hours or so.

The Endocrine Society's clinical practice guideline on acromegaly recommends IGF-1 as the single best screening test for GH excess. The AACE/ACE guidelines on GH deficiency in adults use IGF-1 both to support the diagnosis and to guide replacement dosing.

For women, the test carries additional weight because the GH/IGF-1 axis is directly modulated by estrogen levels, menstrual cycle phase, and pregnancy. A result that looks "low-normal" in a 45-year-old perimenopausal woman on oral estrogen may be falsely suppressed and not reflect true GH output at all.

The Liver Is the Key Production Site

The liver produces roughly 75 percent of circulating IGF-1. Anything that impairs liver function, including alcoholic liver disease, non-alcoholic steatohepatitis, or severe malnutrition, will reduce IGF-1 independently of GH status. This is not a GH deficiency. It is a production problem, and the distinction matters clinically.

IGF-1 Versus IGF-BP3

IGF-1 almost always travels bound to insulin-like growth factor binding protein 3 (IGF-BP3). Some labs run both. IGF-BP3 is slightly less sensitive to estrogen suppression, which occasionally makes it a useful companion in women on oral estrogen therapy. A 2012 analysis in the Journal of Clinical Endocrinology and Metabolism found that IGF-BP3 was less affected by route of estrogen delivery than IGF-1 itself, supporting the value of the paired measurement when oral estrogen is in the picture.

Normal IGF-1 Range by Life Stage in Women

There is no single universal number. Reference ranges are age-stratified and assay-specific. Every lab has its own validated reference interval; the figures below reflect commonly cited population data and should be interpreted alongside your specific lab's range.

| Life Stage | Approximate IGF-1 Range (ng/mL) | |---|---| | Reproductive years (20 to 40) | 116 to 288 | | Perimenopause (40 to 52) | 94 to 252 | | Post-menopause (52 and older) | 71 to 200 | | Pregnancy (second trimester) | can exceed 300 due to placental GH | | Adolescence (peak at puberty) | 200 to 600+ |

The Endocrine Society reference range consensus notes that IGF-1 peaks in mid-puberty and then declines by approximately 14 percent per decade in adulthood. By age 60, many healthy women will sit in the lower third of the "adult normal" range. This is physiologically expected, not automatically pathological.

Why this matters for you: A number that looks alarming in the abstract may be exactly appropriate for your age. The relevant question is whether your level is low (or high) relative to other women of your age, not relative to a 25-year-old athlete.

Perimenopause and Post-Menopause

Estrogen drives GH pulsatility, particularly overnight secretion. As estrogen falls in perimenopause, GH pulse amplitude drops and IGF-1 follows. A longitudinal study published in the Journal of Clinical Endocrinology and Metabolism documented a 14 percent mean reduction in IGF-1 across the menopause transition independent of aging alone. This is one reason some longevity-oriented clinicians track IGF-1 as part of a post-menopausal metabolic panel.

Pregnancy

Placental GH (a distinct isoform from pituitary GH) rises progressively through the second and third trimesters and can push IGF-1 well above typical adult reference ranges. A 2009 paper in Clinical Endocrinology showed that serum IGF-1 peaks around 28 to 32 weeks gestation and then falls sharply after delivery. Interpreting an IGF-1 run during pregnancy without knowing gestational age is clinically meaningless.

Drugs That Raise IGF-1

Several drug classes push IGF-1 upward. When you are taking any of these, a high or high-normal IGF-1 may reflect the drug rather than a true GH-excess state.

Exogenous Growth Hormone and GH-Releasing Peptides

Recombinant human GH (somatropin) directly raises IGF-1, which is how Endocrine Society GH-replacement guidelines recommend titrating the dose: target an IGF-1 in the mid-normal range for age and sex. The Endocrine Society states explicitly that the dose should be adjusted to maintain serum IGF-1 in the normal range.

GH-releasing peptides and secretagogues, including ipamorelin, CJC-1295, sermorelin, tesamorelin, and MK-677 (ibutamoren), stimulate pituitary GH secretion and raise IGF-1 dose-dependently. A randomized trial of MK-677 in older adults showed IGF-1 increases of 39 to 89 percent over baseline depending on dose. If you are using any of these compounds, your IGF-1 will be elevated by design. The clinical question is whether it is elevated too far.

Insulin and Insulin-Sensitizing Agents

Insulin and the growth factor receptor share structural homology, and insulin itself is a positive regulator of IGF-1 production in the liver. High circulating insulin, whether from exogenous injections or endogenous hyperinsulinemia (as in PCOS), tends to raise IGF-1 modestly.

Metformin presents a more complex picture. A 2014 meta-analysis in Diabetes Care found that metformin reduces circulating IGF-1 and IGF-1/IGF-BP3 ratio, possibly via AMPK-mediated suppression of hepatic GH signaling. If you have PCOS and start metformin, expect your IGF-1 to dip somewhat, which may improve androgen-mediated acne or hirsutism.

Thyroid Hormone Replacement

Thyroxine (T4) and triiodothyronine (T3) increase hepatic sensitivity to GH signaling. Women with hypothyroidism have lower IGF-1. Initiating or increasing levothyroxine typically raises IGF-1 by 15 to 25 percent, sometimes enough to move a "low" result into normal range. A study in Thyroid confirmed this relationship and recommended that IGF-1 testing in hypothyroid women be deferred until they are euthyroid on stable therapy.

Drugs That Lower IGF-1

This is where interpretation errors are most common in women's health. Three drug categories that many women take routinely, oral estrogen, glucocorticoids, and somatostatin analogs, can suppress IGF-1 significantly enough to mimic GH deficiency on paper.

Oral Estrogen: The Most Clinically Significant Suppressor in Women

Oral estrogen (including combined oral contraceptives and oral menopausal hormone therapy) reduces hepatic IGF-1 production by suppressing GH receptor sensitivity in the liver, a phenomenon called estrogen-induced GH resistance at the hepatic level. Critically, this is a route-of-effect, not simply an estrogen-effect. Transdermal estrogen, which bypasses first-pass hepatic metabolism, does not suppress IGF-1 to the same degree.

A landmark randomized crossover study in the Journal of Clinical Endocrinology and Metabolism compared oral versus transdermal estradiol in postmenopausal women and found that oral estradiol reduced IGF-1 by approximately 25 to 40 percent, while transdermal estradiol produced no significant change.

This has two major practical implications:

1. If you are on oral contraceptive pills and your IGF-1 comes back low, the pill is the most likely explanation. Switching to a non-oral route before retesting may be warranted before pursuing a workup for GH deficiency.
2. Women receiving GH replacement therapy should preferably use transdermal rather than oral estrogen, or their GH dose requirement will be falsely elevated by the suppressed IGF-1 signal. The Endocrine Society's GH guidelines explicitly note this interaction.

Glucocorticoids

Prednisone, dexamethasone, hydrocortisone, and inhaled corticosteroids at high doses all suppress GH secretion and reduce IGF-1. A study in Clinical Endocrinology found IGF-1 reductions of 20 to 35 percent in patients on chronic oral glucocorticoid therapy. Women with autoimmune conditions, asthma, or inflammatory bowel disease who take steroids long-term may show persistently low IGF-1 without true GH axis pathology.

Somatostatin Analogs

Octreotide and lanreotide are used specifically to treat acromegaly (excess IGF-1) and some neuroendocrine tumors. They suppress GH secretion potently. If you are on these drugs, a low or low-normal IGF-1 is the expected therapeutic endpoint, not a diagnostic concern.

GLP-1 Receptor Agonists (Semaglutide, Tirzepatide, Liraglutide)

This is an area where the evidence is still developing, and that uncertainty deserves direct acknowledgment. Several small studies suggest that GLP-1 agonists may modestly reduce IGF-1, plausibly through effects on insulin and hepatic glucose metabolism. A 2022 study in Obesity found a mean IGF-1 reduction of approximately 12 percent after 26 weeks of semaglutide in women with obesity, though the mechanism is not fully established. Large randomized data in women specifically are lacking. If you are on a GLP-1 agonist and have borderline-low IGF-1, this drug interaction should be part of the clinical discussion.

Anticonvulsants and Mood Stabilizers

Valproic acid, carbamazepine, and to a lesser extent levetiracetam have been associated with reductions in IGF-1 in women with epilepsy. A study in Epilepsia found that women on valproate had IGF-1 levels approximately 20 percent lower than healthy controls, with evidence of disrupted GH pulsatility. Women with epilepsy on these agents who are also being evaluated for GH status need this drug interaction documented clearly in their chart.

Why IGF-1 Matters Specifically for Women with PCOS

PCOS sits at the intersection of insulin resistance, androgen excess, and disrupted GH signaling. A meta-analysis in Human Reproduction Update found that women with PCOS have, on average, higher fasting IGF-1 and lower IGF-BP1 compared with reproductively normal women, a pattern that amplifies free androgen exposure and compounds insulin resistance.

Why does this matter practically? The IGF-1 receptor and the insulin receptor cross-activate in ovarian theca cells. Elevated IGF-1, driven by hyperinsulinemia, stimulates excess androgen production. This is why interventions that lower insulin, whether metformin, dietary carbohydrate reduction, or GLP-1 agonists, also tend to lower IGF-1 and reduce androgen levels in PCOS. Tracking IGF-1 alongside fasting insulin and DHEA-S gives a more complete metabolic picture than androgens alone.

IGF-1 in the Context of GH Peptide Therapy and Longevity Medicine

GH-releasing peptides have moved from anti-aging clinic curiosity to mainstream telehealth offering. Women are using ipamorelin, CJC-1295, sermorelin, and MK-677 for body composition, sleep quality, and recovery. The primary monitoring tool for all of these is IGF-1.

The Endocrine Society's position is that GH therapy is approved only for diagnosed GH deficiency, Turner syndrome, short bowel syndrome, and HIV-associated wasting. Off-label use for longevity is not endorsed by any major guideline body, but it is happening in clinical practice. The AACE recommends that anyone receiving GH-axis-active therapy have IGF-1 monitored at baseline, at 4 to 6 weeks after starting or dose changes, and then every 6 months when stable.

For women specifically, the target IGF-1 while on GH or GH-releasing therapy should be in the age-appropriate mid-normal range, not the top of the range and certainly not above it. There is a theoretical concern, based on epidemiological data rather than RCTs, that persistently supraphysiologic IGF-1 may increase breast cancer risk. A meta-analysis in The Lancet Oncology found that higher circulating IGF-1 was associated with a modest but statistically significant increase in premenopausal breast cancer risk (relative risk approximately 1.28 per standard deviation increase). This does not establish causality, and the absolute risk is small, but it is a reason to aim for the middle of the range rather than the top.

Pregnancy, Lactation, and Contraception Considerations

Pregnancy: IGF-1 testing during pregnancy requires specific interpretation. As noted above, placental GH raises IGF-1 in the second and third trimesters, sometimes substantially above the non-pregnant adult reference range. This is physiological. Acromegaly diagnosed in pregnancy is rare but does occur; when GH excess is suspected in a pregnant woman, tumor markers and pituitary MRI (without gadolinium in the first trimester) are part of the workup. ACOG guidance on pituitary disorders in pregnancy should be consulted.

Somatostatin analogs (octreotide, lanreotide) used to treat acromegaly are generally avoided in pregnancy because of limited safety data and theoretical concern about suppression of fetal GH. If you have known acromegaly and are planning pregnancy, this requires subspecialty co-management between your endocrinologist and your OB before conception.

GH-releasing peptides such as ipamorelin and CJC-1295 have no established human safety data in pregnancy. They should not be used while pregnant or attempting conception.

Lactation: Human milk contains IGF-1 at physiologically relevant concentrations, and this is considered a normal part of its growth-promoting composition. Exogenously administered GH in a breastfeeding mother will raise serum IGF-1, but oral bioavailability of ingested IGF-1 in the infant is very low due to proteolytic degradation in the gut. Still, GH or GH-peptide use is not recommended during lactation due to the absence of safety data.

Contraception: Women using GH-releasing peptides off-label should use effective contraception. Somatostatin analogs require reliable contraception during treatment given their teratogenic potential in animal studies and the absence of human safety data. Oral contraceptives are an effective option but, as discussed above, will suppress IGF-1 by 25 to 40 percent and confound test interpretation. Non-oral hormonal methods (patch, ring, IUD, implant) or barrier methods are preferable if accurate IGF-1 monitoring is a priority.

How to Raise or Lower IGF-1 Without Drugs

Women sometimes want to move their IGF-1 without pharmaceutical intervention, either because it is borderline low (a longevity concern) or borderline high (a cancer-risk concern after reading epidemiological data).

To modestly raise IGF-1:

• Resistance training three or more sessions per week raises IGF-1 by 10 to 20 percent in previously sedentary women. A 2010 RCT in the Journal of Strength and Conditioning Research confirmed this response.
• Adequate dietary protein, at least 1.2 g per kg body weight per day, is necessary for hepatic IGF-1 synthesis. Severe caloric restriction drops IGF-1 quickly.
• Correcting hypothyroidism, if present, will restore IGF-1 toward normal.
• Switching from oral to transdermal estrogen, if appropriate for your clinical situation, can raise IGF-1 by 20 to 35 percent in women on MHT.

To modestly lower IGF-1:

• Sustained aerobic exercise combined with modest caloric deficit reduces IGF-1.
• Caloric restriction alone reduces IGF-1 significantly, though this also reduces lean mass.
• Metformin in women with hyperinsulinemia or PCOS reduces IGF-1.
• Increasing dietary fiber and reducing refined carbohydrates lowers insulin, which in turn reduces IGF-1 modestly.

Who Should and Should Not Act on an IGF-1 Result

Not every IGF-1 result needs a response. The following framework helps clarify who needs further workup versus who needs medication reconciliation first.

Act on the result (refer to endocrinology) if:

• IGF-1 is high and you have symptoms of acromegaly: jaw growth, ring size changes, sleep apnea, carpal tunnel syndrome, new-onset type 2 diabetes
• IGF-1 is low, confirmed on repeat testing off suppressing medications, with symptoms: fatigue, body composition changes, poor bone density, low quality of life scores

Repeat the test after medication reconciliation if:

• You are on oral contraceptives or oral menopausal hormone therapy
• You are taking glucocorticoids or anticonvulsants
• You recently changed thyroid hormone dose
• You are on semaglutide or another GLP-1 agonist
• You are pregnant or recently postpartum

A note on evidence gaps: Most of the drug-interaction data for IGF-1 comes from studies in mixed-sex populations or, in some cases, exclusively in men. The GLP-1 and IGF-1 interaction data in women specifically is very thin. The anticonvulsant data is somewhat better given that women with epilepsy have been studied as a distinct group. Where the sex-specific data is absent or extrapolated from male cohorts, WomanRx editors have flagged it above. The clinical implication is that the listed suppression percentages should be treated as estimates rather than precise predictions for any individual woman.